Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH20 phase 2 study of poziotinib in EGFR or HER2 exon 20-mutant NSCLC
NL-OMON55568Phase 2Active, not recruiting
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of poziotinib in non-small cell lung cancer (NSCLC) (7 arms), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Objective Response Rate. Started Jan 2019; status: active, not recruiting.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55568.